Centuria

Fund Update September 2022

Centuria Healthcare Medical Development Fund No.1



- As at 30 June 2022, the Fund's Net Asset Value (NAV) is \$0.7958 per unit¹
- Discussions are continuing with the anchor tenant a joint venture between local surgeons and a hospital operator
- The hospital operator has engaged a consultant to assist in attracting further surgeons
- 1 Based on unaudited accounts as at 30 June 2022.

Fund summary

Leasing update

During the quarter, the Manager and Pikos (Project Partners) have continued discussions with the proposed anchor tenant – a joint venture between an established and well capitalised hospital operator and a local surgeon group – which is proposed to occupy approximately 29% of the to-be developed property.

While the discussions continue to be protracted, there has been meaningful progress since our last semi-annual update, as outlined below:

- 17 surgeons are contracted (up from 7 to 10 surgeons since our last semi-annual update). These surgeons have committed capital to the joint venture entity, creating a strong level of alignment.
- Of the 17 surgeons contracted, there is a broad mix of specialities - 10 are orthopaedic, 6 are a mixture of plastics / ENT / gastroenterology and 1 is a general surgeon.
- To reach a feasible business case, commitment from a further 5 surgeons is required. To achieve this target, the hospital operator has engaged a healthcare consultant to assist in contracting the additional surgeons, specifically targeting ENT and general surgeons.
- We have been advised by the hospital operator, that the process to attract further surgeon commitment should take approximately 6-8 weeks (ending mid-October 2022).

Following the finalisation of surgeon commitments, the anchor tenant will be in a position to confirm its' lease terms at the property which will be documented in the Agreement for Lease (AFL). We anticipate that the AFL will be finalised towards the end of CY2022. After securing the AFL with the proposed anchor tenant, there will be sufficient cause to commence enabling works on the site including excavation for the four-level basement carpark.



In terms of leasing the balance net lettable area of the property, an on-market campaign will commence only after execution of an AFL with the anchor tenant. However, initial informal leasing discussions have been held with a number of other potential tenants at the property, including GP, imaging, pharmacy and specialist groups. We anticipate the on-market campaign will commence in early CY2023, subject to execution of the anchor tenant AFL.

Liquidity

The Manager maintains its focus in achieving a liquidity event for all Fund investors as soon as practically possible. Subject to further analysis and discussions with Fund investors, the Manager is seeking to provide a liquidity option subject to (among other conditions) the satisfaction of the following remaining conditions:

- All development and planning approvals have been obtained (including any preliminary hospital licence approvals required by the proposed anchor tenant);
- agreements for lease have been obtained covering 65% of the property's forecast net property income; and
- terms of a construction contract have been agreed.

A high-level program is as follows:

Item	Status	Information memorandum	Anticipated date
Development application approval	Completed	Dec 2017	Mar 2019
MID approval	Completed	N/A	Apr 2021
Commencement of construction	Not commenced	Jul 2017	Forecast Apr 2023
Practical completion	Not commenced	Sept 2018	Forecast Dec 2024
Expiry of investment term	Progressing	Jun 2019	TBA ¹

² The expiry of the investment term is dependent on a number of factors, including the type of sale (as-is, fund-through or turn-key) and whether a rental guarantee is agreed with the buyer of the property.

Financial snapshot

Fund commencement date	11 April 2017
Net asset value (NAV) (\$ per Unit)	\$0.79581
Investor equity (drawn) (\$m)	15.25

¹ Based on unaudited accounts as at 30 June 2022.

Property details ASSET VALUES

Property addresses	52-64 Annerley Road, Woolloongabba QLD
Independent valuation	\$13.5m
Independent valuation date	24 July 2021
Valuer	Preston Rowe Paterson

Centuria website

Access all your Centuria Healthcare investments information at: Centurialnvestor.com.au.

Contact details

If you require assistance with your Centuria Investor account or have any questions regarding your investment in the Fund, please contact **Centuria Investor Services** on **1800 182 257** or by email on **property.enquiry@centuriainvestor.com.au.**

Disclaimer: This communication has been issued by Centuria Healthcare Asset Management Limited ABN 40 003 976 672 AFSL 246368 (CHAML) as trustee for Centuria Healthcare Medical Development Fund No.1. This communication has been published for information purposes only. The information contained in this communication is of a general nature only and does not constitute financial product advice. In preparing this communication the author has relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which has otherwise been reviewed in preparation of the communication. The information contained in this communication is current as at the date of this communication and is subject to change without notice. Past performance is not a reliable indicator of future performance. Except insofar as liability under any statute cannot be excluded, CHAML, and its associates, related entities, directors, employees and consultants do not accept any liability for any loss or damage (whether direct, indirect, consequential or otherwise) arising from the use of this communication. All investment is subject to investment risk, including possible delays in payment or loss of income and principal invested. None of CHAML or any of their respective associates, related entities or directors guarantee the performance of the Fund or the repayment of monies invested. Before investing the investor should obtain an offer document relating to the product and consider this before making any decision about whether to acquire the product.